secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0000805928-24-000005
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025
--------------------------------------------------------------------------------

- Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.
- Gross margin for FY2023 expected ~80%; 375 Core Accounts (+13% YoY); 116 direct sales reps.
- CEO Karen Zaderej to retire by Jan 2025; Board will search for successor; she will consult for 9 months after transition.
- BLA submission for Avance Nerve Graft on track for H1 2024; Axoguard HA+ and Avive+ product rollouts planned.
- Avance Nerve Graft surpassed 100,000 implants since launch; strong commercial execution cited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/axgn-20240104.htm
  HTML page:      https://secwatch.observer/filing/0000805928-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer